Novartis AG (NOVN) Given Average Rating of “Hold” by Analysts

Novartis AG (VTX:NOVN) has been given a consensus rating of “Hold” by the twenty brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is CHF 90.35.

A number of analysts have recently commented on the company. UBS Group set a CHF 82 price objective on Novartis and gave the stock a “neutral” rating in a research note on Wednesday, November 21st. Barclays set a CHF 80 price objective on Novartis and gave the stock a “neutral” rating in a research note on Thursday, September 20th. Goldman Sachs Group set a CHF 110 price objective on Novartis and gave the stock a “buy” rating in a research note on Monday, November 19th. HSBC set a CHF 84 price objective on Novartis and gave the stock a “neutral” rating in a research note on Wednesday, November 28th. Finally, Kepler Capital Markets set a CHF 90 price objective on Novartis and gave the stock a “buy” rating in a research note on Thursday, September 6th.

Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: Bond

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply